Positions

Selected Publications

Academic Article

Year Title Altmetric
2018 Corrigendum: Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models (Oncology Reports (2018) 40 (1545-1553) DOI: 10.3892/or.2018.6313) 2018
2018 Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models 2018
2017 Lack of chemopreventive efficacy of metformin in rodent models of urinary bladder, head and neck, and colon/intestine cancer 2017
2016 5MeCDDO blocks metabolic activation but not progression of breast, intestine, and tongue cancers. Is antioxidant response element a prevention target? 2016
2015 Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models 2015
2015 Prevention of chemically induced urinary bladder cancers by naproxen: Protocols to reduce gastric toxicity in humans do not alter preventive efficacy 2015
2014 Preventive effects of NSAIDs, NO-NSAIDs, and NSAIDs plus difluoromethylornithine in a chemically induced urinary bladder cancer model 2014
2014 Osteopontin facilitates ultraviolet B-induced squamous cell carcinoma development 2014
2013 Effect of intermittent dosing regimens of erlotinib on methylnitrosourea- induced mammary carcinogenesis 2013
2012 Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers 2012
2011 Effects of 5,6-benzoflavone, indole-3-carbinol (I3C) and diindolylmethane (DIM) on chemically-induced mammary carcinogenesis: Is DIM a substitute for I3C? 2011
2011 Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkers 2011
2010 Screening Agents for Preventive Efficacy in a Bladder Cancer Model: Study Design, End Points, and Gefitinib and Naproxen Efficacy 2010
2010 Establishment and characterization of an osteopontin-null cutaneous squamous cell carcinoma cell line 2010
2009 Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers 2009
2009 Mycoplasma pulmonis and lymphoma in bioassays in rats 2009
2009 Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis 2009
2009 Mycoplasma pulmonis and lymphoma 2009
2008 Rosiglitazone, a PPAR gamma agonist: Potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers 2008
2008 Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers 2008
2008 Effects of gefitinib (Iressa) on mammary cancers: Preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes 2008
2007 Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model 2007
2007 Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols 2007
2006 Papilloma development is delayed in osteopontin-null mice: Implicating an antiapoptosis role for osteopontin 2006
2006 Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: Prevention, therapy, and role of HaRas mutations 2006
2005 4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: Characterization of FHIT and survivin expression and chemopreventive effects of indomethacin 2005
2005 Efficacy of Targretin on methylnitosourea-induced mammary cancers: Prevention and therapy dose-response curves and effects on proliferation and apoptosis 2005
2004 Efficacy of 9-cis-retinoic acid and N-(4-hydroxyphenyl) retinamide alone and in combination in mammary cancer prevention 2004
2004 Letter to the editor (multiple letters) 2004
2002 Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3 2002
2001 Effects of acute and chronic body weight gain reductions in the evaluation of agents for efficacy in mammary cancer prevention. 2001
1999 Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model 1999
1998 Chemopreventive effects of the aromatase inhibitor vorozole (R 83842) in the methylnitrosourea-induced mammary cancer model 1998
1998 Anhydroretinol, a retinoid active in preventing mammary cancer induced in rats by N-methyl-N-nitrosourea 1998
1997 Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer 1997
1997 Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer. 1997
1997 Chemopreventive efficacy of anethole trithione, N-acetyl-L-cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model 1997
1995 Chemoprevention of chemically-induced mammary carcinogenesis by indole-3-carbinol 1995
1993 Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors 1993
1993 Effects of viral and mycoplasmal infections, ammonia exposure, vitamin A deficiency, host age, and organism strain on adherence of Mycoplasma pulmonis in cultured rat tracheas 1993
1992 Effects of folate deficiency and supplementation on methylnitrosourea-induced rat mammary tumors 1992
1991 Effect of canthaxanthin on chemically induced mammary carcinogenesis 1991
1990 Effect of Miso (Japanese Soybean Paste) and NaCl on DMBA-Induced Rat Mammary Tumors 1990
1990 Effect of retinyl acetate and 4-hydroxyphenylretinamide on initiation of chemically-induced mammary tumors 1990
1988 Short-term hormone treatment as a chemopreventive method against mammary cancer initiation in rats 1988
1986 Suppression by pregnancy of chemically induced preneoplastic cells of the rat mammary gland. 1986
1985 Nonspecific lymphocyte responses in F344 and LEW rats: Susceptibility to murine respiratory mycoplasmosis and examination of cellular basis for strain differences 1985
1981 Tumorigenicity of 7, 12-dimethylbenz[a]anthracene, its hydroxy-methylated derivatives and selected dihydrodiols in the newborn mouse 1981
1978 M. M. JULIANA 1978
1978 M. M. JULIANA 1978
1977 Polycystic kidney disease in a cat 1977

Investigator On

  • PREVENT Cancer Preclinical and Drug Development Program  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • TORFP 2019-E03 Evaluation of Two Different Classes of Compounds (STAT3 Inhibitors and SERMs) for Prevention of Urinary Bladder Cancer  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • TORFP 2019-E04 Colorectal Cancer Prevention by Novel EPA Analogue TP-252 and Naproxen in FAP and Lynch Syndrone Models  awarded by National Cancer Institute/NIH/DHHS 2019 - 2024
  • Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T002 HHSN2610002 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-02 - Evaluation of Agents/Protocols that Inhibity the Two Major Pathways Involved in Human Urinary Bladder Cancer [PI3K, EGFR] and Protocols to Reduce their Toxicity  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • T003 HHSN2610003 Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers - Task Order 2015 E-07 - Evaluation of the Cancer Prevention Efficacy of GLG-302  awarded by National Cancer Institute/NIH/DHHS 2015 - 2021
  • HHSN26100002 Efficacacy of a Multi-Antegen Vaccine in the Prevention of MethyInitrosourea-Introduced Mammary Cancers (ER+) in Female Sprague-Dawley Rats  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100003 Chemopreventive Effects in Both Standard Chow Diets and High Fat Diets of Known Positive and Negative Chemopreventative Agents Employing Both High Risk (But Histologically Normally) Mammary Epithelium and Mammary Cancers Including Correlative Biomarkers  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100004 TORFP IV/IV 2013-3 Evaluation of GLG-302, a STAT3 Antagonist in the Prevention of Mammary Cancer  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100005 TORFP IV/IV 2013-4 Efficacy of Metformin in the Methylnitrosourea-Induced Model EF+ Mammary Carcinogenesis when Animals are Placed on Different Diets: Standard Diet, High Fat Diet, and High Fructose Diet  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100006 TORFP 2014-3I Evaluation of the Prevention by Actoplus/Met (Pioglitazone and Metformin) of ER+ and ER- Mammary Cancer Occurring in Rodents on a High-Fat Diet  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • HHSN26100007 TORFP 2014-5I Effect of Bazedoxifene Either Alone or in Combination with an Aromatase Inhibitor or Conjugated Estrogens (CE) in the Prevention of Mammary Cancers  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Preclinical in Vitro and In Vivo Agent Development Assays  awarded by National Cancer Institute/NIH/DHHS 2014 - 2017
  • Full Name

  • M Juliana